67 results
DEFM14A
GHSI
Guardion Health Sciences Inc
8 Apr 24
Proxy related to merger
4:28pm
” means, without duplication and only to the extent incurred or subject to reimbursement by the Company and not paid prior to the Adjustment Time … party professional advisors including all brokerage fees, commissions, or finders’ fee incurred by (or subject to reimbursement by) the Company
PREM14A
GHSI
Guardion Health Sciences Inc
20 Mar 24
Preliminary proxy related to merger
8:15pm
in the computation of Working Capital.
“Transaction Expenses” means, without duplication and only to the extent incurred or subject to reimbursement … by (or subject to reimbursement by) the Company in connection with the Transactions, and (ii) any discretionary, transaction or change of control
425
EX-10.1
GHSI
Guardion Health Sciences Inc
31 Jan 24
Business combination disclosure
5:21pm
or subject to reimbursement by the Company and not paid prior to the Adjustment Time, whether accrued for or not, the collective amount of all (i) costs … , commissions, or finders’ fee incurred by (or subject to reimbursement by) the Company in connection with the Transactions, and (ii) any discretionary
8-K
EX-10.1
GHSI
Guardion Health Sciences Inc
31 Jan 24
Entry into a Material Definitive Agreement
5:18pm
or subject to reimbursement by the Company and not paid prior to the Adjustment Time, whether accrued for or not, the collective amount of all (i) costs … , commissions, or finders’ fee incurred by (or subject to reimbursement by) the Company in connection with the Transactions, and (ii) any discretionary
8-K
EX-10.1
adyel6bm62
26 Sep 23
Departure of Directors or Certain Officers
4:30pm
8-K
EX-10.1
lkcuixe7lb7m
31 Jul 23
Departure of Directors or Certain Officers
5:20pm
8-K
EX-10.1
pkgql ze4xs0auyg2
30 May 23
Guardion Health Sciences Announces Appointment of Former Neutrogena and Coca-Cola Executive Jan Hall
5:29pm
8-K
EX-10.1
oh1d0l16z9qn7my
2 Dec 22
Entry into a Material Definitive Agreement
5:02pm
424B5
t9kaagh236 7n1
24 Feb 22
Prospectus supplement for primary offering
4:30pm
8-K
EX-4.4
x80mawl5duxccqlww8
23 Feb 22
Guardion Health Sciences, Inc. Announces Proposed Public Offering
5:24pm
8-K
EX-10.1
41y 966u9zp3
23 Feb 22
Guardion Health Sciences, Inc. Announces Proposed Public Offering
5:24pm
8-K
EX-10.2
k6zwqag
23 Feb 22
Guardion Health Sciences, Inc. Announces Proposed Public Offering
5:24pm
424B5
yhk22mx48c1tm
22 Feb 22
Prospectus supplement for primary offering
5:28pm
424B5
ekvpu8f darq
17 Feb 22
Prospectus supplement for primary offering
8:30am
8-K
EX-10.1
9vg5v59 mqlspzwg
2 Aug 21
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.1
7flu1a1jdqu5
21 May 21
Acquisition to Transform and Strengthen Guardion’s Clinical Nutrition Product Portfolio
4:05pm